



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s)

Marianna Maranghi

Work Address(es)

Residence Address

E-mail

Nationality

Gender

Current employer

Date since employed

Occupational field

Sapienza University of Rome, Italy

September 2019

**Associate Professor in Internal Medicine–
Internal Medicine and Metabolic Disease Unit SMSC01
Policlinico Umberto I Hospital, Rome**

Current employer

Date since employed

Occupational Field

Azienda Policlinico Umberto I- Rome

April 2015

**Medical Assistant at the Department of Internal Medicine and Medical Specialties –
Outpatient Internal Medicine and Metabolic Disease Clinic and Inpatient Internal
Medicine and Metabolic Disease Clinic SMSC01**

Work experience

Dates

From March 2010 to May 2011

Occupation or position held

Post doctoral Research position at Sapienza University Rome

Main activities and responsibilities

Coordination of the clinical outpatient activities and of cardiovascular non-invasive diagnostics in type 2 diabetes

Name and address of employer

Outpatients department for Diabetes and Endocrinology, Internal Medicine and Medical Specialties Department
Policlinico Umberto I Hospital – Sapienza University, Rome

Type of business or sector

University hospital

Dates

From January 2009 to February 2010

Occupation or position held

Post-doctoral Research Fellow at the Department of Internal Medicine- University of Helsinki Biomedicum-
working on a project entitled "Diabetic dyslipidemia and metabolic control" under the supervision of Professor
Marjia Riitta Taskinen

Main activities and responsibilities

Researcher

Name and address of employer

Professor M.R. Taskinen

Type of business or sector

Internal Medicine

Dates

From February 2007 to December 2009

Occupation or position held

Medical director, grade 1

Main activities and responsibilities

Coordination of the Cardiovascular Prevention Clinic Policlinico Umberto I Rome

Name and address of employer

Department of Clinical Science - Policlinico Umberto I Hospital– Sapienza University, Rome

Type of business or sector

University hospital

Last ICH-GCP training: 2026; Provider Novonordisk

Clinical Trials

Novo Nordisk- NN2211-1860	2008-2010	The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Subjects With Type 2 Diabetes
Bayer-ARRIVE	2008-2014	Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease
Novo Nordisk- NN1250-3582	2008-2010	Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment
Novo Nordisk- 12503667	2009-2011	An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine in Type 2 Diabetes
Novartis- CLAF237B222 4	2008-2010	Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Merck- MK0431.102	2009-2010	Study of the Co-Administration of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mellitus
NovoNordisk- EX2211-3748	2010-2016	Liraglutide Effect on Cardiovascular Events
Merck- MK0431.403	2011-2012	Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus
Merck- MK0431.260	2012-2013	To Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus
Novartis- CLAF237A 23156	2015-2020	Durability of Glycemic Control of a Combination Regimen With Vildagliptin & Metformin Versus Standard-of-care Monotherapy With Metformin, Initiated in Treatment-naïve Patients With Type 2 Diabetes Mellitus
Novo Nordisk- 1250-3944	2012-2013	The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes
Merck- MK3102-018	2013-2016	Study to Assess Cardiovascular Outcomes With MK-3102 in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk- NN9535-3624	2013-2015	Efficacy and safety of semaglutide once-weekly versus exenatide ER 2.0 mg once-weekly as add-on to 1-2 oral antidiabetic drugs (OADs) in subjects with type 2 diabetes
Novo Nordisk- NN9924-3790	2013-2014	Multiple dose trial examining dose range, escalation and efficacy of oral semaglutide (NNC0113-0217) in subjects with type 2 diabetes
Novo Nordisk- EX1250-4080	2014-2016	A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events
Novonordisk EX9924-4473	2019-2024	Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes

Novo Nordisk NN1436-4466	2019-2020	A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
Novo Nordisk NN436-4477	2020-2023	A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with non-insulin anti-diabetic treatment, in insulin naïve subjects with type 2 diabetes.
Novo Nordisk NN1535-4988	2024-2025	A 40-week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Daily Insulin Glargine 100 Units/mL in Participants With Type 2 Diabetes Inadequately Controlled on Oral Anti Diabetic Drugs COMBINE 4

Degrees

Dates	2011
Title of qualification awarded	Master degree in Diabetology
Name and type of organisation providing education and training	Sapienza University , Rome
Dates	2005-2008
Title of qualification awarded	Ph.D. Degree in Biomedical Technologies and Clinical Medicine
Name and type of organisation Providing education and training	Sapienza University , Rome
Dates	2008
Title of qualification awarded	NLA Master in Lipidology Advanced Training and Board Review Course
Name and type of organization providing education and training	National Lipid Association
Dates	2000 – 2005
Title of qualification awarded	Board in Internal Medicine
Name and type of organisation providing education and training	Sapienza University , Rome
Dates	1994 – 2000
Title of qualification awarded	Master Degree in Medicine and Surgery

Name and type of organisation providing education and training

Sapienza University, Rome

Dates

1989 – 1994

Title of qualification awarded

High School Leaving Qualification with specialization in Classical studies

Name and type of organisation providing education and training

Liceo Ginnasio Statale Dante Alighieri di Roma

Awards and Honors

Dates

2023-ongoing

Coinvestigator for Sapienza at the European Call HORIZON-HLTH-2023-TOOL-05-03 – dAlbetes

Umberto Di Mario Foundation” Prize.

2005

Marcello Santoro Prize, SISA Foundation

2012

Dates

Membership of Scientific-Professional Societies

Italian Internal Medicine Society
Italian society for the study of atherosclerosis
European Atherosclerosis Society
Associazione Medici Diabetologi (AMD)

Teaching activities

Dates

2024-ongoing

Vice President
“F” Course of Medicine Sapienza University

Dates

2024-ONGOING

VICE PRESIDENT
F COURSE OF MEDICINE SAPIENZA UNIVERSITY ROME

2021- ongoing

Excellence Course Coordinator

Dates

“F” Course of Medicine Sapienza University

2007-2014

Internal Medicine III

“A” Course of Medicine Sapienza University

2015-2016

Internal Medicine III
B Course of Medicine Sapienza University

2013-ongoing
Internal Medicine in Geriatrics
Undergraduate Physiotherapy Course
S. Giovanni Addolorata
Sapienza University

2016-ongoing
Internal Medicine and Surgery III
F Course of Medicine Sapienza University

2018-ongoing
AMSM1
F Course of Medicine Sapienza University

Personal skills and competences

Mother tongue(s)

Italian

Other language(s)

English

Self-assessment

European level (*)

English

Understanding		Speaking				Writing	
Listening		Reading		Spoken interaction		Spoken production	
A1		A1		A1		A1	

(*) [Common European Framework of Reference for Languages](#)

Computer skills and competences

Good working knowledge of the Internet and e-mail tools, as well as of the Office Package both in Windows and Mac OS, mainly used for the following purposes: to draft scientific articles and documentation; to process statistical data with Excel sheets and SPSS software and to create presentations for conferences and academic lessons.

Driving licence

B

**Additional information
Voluntary Work**

- 2001 Three months voluntary fellow at the Laboratory of the Department of Clinical Pharmacology – Trinity College Dublin under the supervision of Professor D. Fitzgerald.
- 2006 One month voluntary clinical working experience at the Center for Human Nutrition – The University of Texas, Southwestern Medical Center (Dallas, USA) under the supervision of Professor N. Abate.
- Sailing instructor at Centro Velico Caprera Sailing School Italy

Scientific Publications

1. Verrienti A, Pecce V, Grani G, Del Gatto V, Barp S, Maranghi M, Giacomelli L, Di Gioia C, Biffoni M, Filetti S, Durante C, Sponziello M. Serum microRNA-146a-5p and microRNA-221-3p as potential clinical biomarkers for papillary thyroid carcinoma. *J Endocrinol Invest*. 2025 Mar;48(3):619-631.
2. Acitelli E, Verrienti A, Sponziello M, Pecce V, Minicocci I, Macera M, Barp S, Lucia P, Grani G, Durante C, Maranghi M. Effects of lenvatinib on glucose, cholesterol, triglycerides and estimated cardiovascular risk in patients with advanced thyroid cancer. *Endocrine* Feb 87(2):619-626
3. Acitelli E, Guedon AF, De Liguori S, Gallo A, Maranghi M. Peripheral artery disease: an underdiagnosed condition in familial hypercholesterolemia? A systematic review. *Endocrine*. 2024 Jul;85(1):122-133.
4. D'Erasmus L, Di Martino M, Neufeld T, Fraum TJ, Kang CJ, Burks KH, Di Costanzo A, Minicocci I, Bini S, Maranghi M, Pigna G, Labbadia G, Zheng J, Fierro D, Montali A, Ceci F, Catalano C, Davidson NO, Lucisano G, Nicolucci A, Arca M, Stitzel NO. ANGPTL3 Deficiency and Risk of Hepatic Steatosis. *Circulation*. 2023 Nov 7;148(19):1479-1489.
5. Rosenstock J, Bain SC, Gowda A, Jódar E, Liang B, Lingvay I, Nishida T, Trevisan R, Mosenzon O; ONWARDS 1 Trial Investigators. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. *N Engl J Med*. 2023 Jul 27;389(4):297-308.
6. Acitelli E, Maiorca C, Grani G, Maranghi M. Metabolic adverse events of multitarget kinase inhibitors: a systematic review. *Endocrine*. 2023 Jul;81(1):16-29. doi: 10.1007/s12020-023-03362-2. Epub 2023 Apr 17.
7. Grani G, Cera G, Conzo G, Del Gatto V, di Gioia CRT, Maranghi M, Lucia P, Cantisani V, Metere A, Melcarne R, Borcea MC, Scorziello C, Menditto R, Summa M, Biffoni M, Durante C, Giacomelli L. Preoperative Ultrasonography in the Evaluation of Suspected Familial Non-Medullary Thyroid Cancer: Are We Able to Predict Multifocality and Extrathyroidal Extension? *J Clin Med*. 2021 Nov 13;10(22):5277. doi: 10.3390/jcm10225277. PMID: 34830559
8. Bruttomesso D, Irace C, Pozzilli P; SAGE study group. A sub-analysis of the SAGE study in Italy indicates good glycemic control in type 1 diabetes. *Nutr Metab Cardiovasc Dis*. 2023 Mar;33(3):631-639. doi: 10.1016/j.numecd.2022.11.008. Epub 2022 Nov 17.
9. D'Erasmus L, Minicocci I, Di Costanzo A, Pigna G, Commodari D, Ceci F, Montali A, Brancato F, Stanca I, Nicolucci A, Ascione A, Galea N, Carbone I, Francone M, Maranghi M, Arca M. Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events. *J Am Heart Assoc*. 2021 May 4;10(9)
10. Grani G, Brenta G, Trimboli P, Falcone R, Ramundo V, Maranghi M, Lucia P, Filetti S, Durante C. Sonographic Risk Stratification Systems for Thyroid Nodules as Rule-Out Tests in Older Adults. *Cancers (Basel)*. 2020 Aug 30;12(9):2458.
11. D'Erasmus L, Commodari D, Di Costanzo A, Minicocci I, Polito L, Ceci F, Montali A, Maranghi M, Arca M. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study. *Nutr Metab Cardiovasc Dis*. 2020 Oct 30;30(11):2027-203
12. Grani G, Lamartina L, Ramundo V, Falcone R, Lomonaco C, Ciotti L, Barone M, Maranghi M, Cantisani V, Filetti S, Durante C. Taller-Than-Wide Shape: A New Definition Improves the Specificity of TIRADS Systems. *Eur Thyroid J*. 2020 Feb;9(2):85-91
13. Lenzi A, Maranghi M, Stilo G, Velardi P. The social phenotype: Extracting a patient-centered perspective of diabetes from health-related blogs. *Artif Intell Med*. 2019 Nov;101:101727. doi: 10.1016/j.artmed.2019.101727. Epub 2019 Oct 24.

14. Rodríguez-Rodríguez I, Chatzigiannakis I, Rodríguez JV, Maranghi M, Gentili M, Zamora-Izquierdo MÁ. Utility of Big Data in Predicting Short-Term Blood Glucose Levels in Type 1 Diabetes Mellitus Through Machine Learning Techniques. *Sensors (Basel)*. 2019 Oct 16;19(20).
15. Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, Lingvay I, Søndergaard AL, Treppendahl MB, Montanya E; PIONEER 2 Investigators. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. *Diabetes Care*. 2019 Sep 17. pii: dc190883. doi: 10.2337/dc19-0883.
16. Grani G, Tumino D, Ramundo V, Ciotti L, Lomonaco C, Armillotta M, Falcone R, Lucia P, Maranghi M, Filetti S, Durante C. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments. *J Endocrinol Invest*. 2019 Jun 15. doi: 10.1007/s40618-019-01074-x.
17. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbøll T, Warren ML, Bain SC; PIONEER 6 Investigators. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med*. 2019 Aug 29;381(9):841-851. doi: 10.1056/NEJMoa1901118. Epub 2019 Jun 11.
18. Celano M, Maggisano V, Lepore SM, Sponziello M, Pecce V, Verrienti A, Durante C, Maranghi M, Lucia P, Bulotta S, Damante G, Russo D. Expression of Leptin Receptor and Effects of Leptin on Papillary Thyroid Carcinoma Cells. *Int J Endocrinol*. 2019 Feb 14;2019:5031696. doi: 10.1155/2019/5031696
19. Lai C, Filippetti G, Schifano I, Aceto P, Tomai M, Lai S, Pierro L, Renzi A, Carnovale A, Maranghi M. Psychological, emotional and social impairments are associated with adherence and healthcare spending in type 2 diabetic patients: an observational study. *Eur Rev Med Pharmacol Sci*. 2019 Jan;23(2):749-754. doi: 10.26355/eurrev_201901_16889.
20. Ramundo V, Lamartina L, Falcone R, Ciotti L, Lomonaco C, Biffoni M, Giacomelli L, Maranghi M, Durante C, Grani G. Is thyroid nodule location associated with malignancy risk? *Ultrasonography*. 2019 Jul;38(3):231-235. doi:10.14366/usg.18050.
21. Maggisano V, Celano M, Lepore SM, Sponziello M, Rosignolo F, Pecce V, Verrienti A, Baldan F, Mio C, Allegri L, Maranghi M, Falcone R, Damante G, Russo D, Bulotta S. Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells. *Endocrine*. 2019 Mar;63(3):545-553. doi: 10.1007/s12020-018-01836-2. Epub 2019 Jan 19.
22. Maranghi M, Truglio G, Gallo A, Grieco E, Verrienti A, Montali A, Gallo P, Alesini F, Arca M, Lucarelli M. A novel splicing mutation in the ABCA1 gene, causing Tangier disease and familial HDL deficiency in a large family. *Biochem Biophys Res Commun*. 2019 Jan 8;508(2):487-493. doi: 10.1016/j.bbrc.2018.11.064.
23. Lamartina L, Montesano T, Falcone R, Biffoni M, Grani G, Maranghi M, Ciotti L, Giacomelli L, Ramundo V, Lomonaco C, Di Gioia CR, Piernatale L, Ronga G, Durante C. Is it worth suppressing tsh in low- and intermediate-risk papillary thyroid cancer patients before the first disease assessment? *Endocr Pract*. 2019 Feb;25(2):165-169. doi: 10.4158/EP-2018-0393.
24. Grani G, Lamartina L, Ascoli V, Bosco D, Biffoni M, Giacomelli L, Maranghi M, Falcone R, Ramundo V, Cantisani V, Filetti S, Durante C. Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the "Right" TIRADS. *J Clin Endocrinol Metab*. 2019 Jan 1;104(1):95-102. doi: 10.1210/jc.2018-01674.
25. Grani G, Lamartina L, Montesano T, Ronga G, Maggisano V, Falcone R, Ramundo V, Giacomelli L, Durante C, Russo D, Maranghi M. Lack of association between obesity and aggressiveness of differentiated thyroid cancer. *J Endocrinol Invest*. 2018 Apr 17.
26. Grani G, Lamartina L, Cantisani V, Maranghi M, Lucia P, Durante C. Interobserver agreement of various thyroid imaging reporting and data systems. *Endocr Connect*. 2018 Jan;7(1):1-7.
27. Pirillo A, Garlaschelli K, Arca M, Averna M, Bertolini S, Calandra S, Tarugi P, Catapano AL; LIPIGEN Group. Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. *Atheroscler Suppl*. 2017 Oct;29:17-24.
28. Averna M, Cefalù AB, Casula M, Noto D, Arca M, Bertolini S, Calandra S, Catapano AL, Tarugi P; LIPIGEN Group. Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). *Atheroscler Suppl*. 2017 Oct;29:11-16.

29. Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Liraglutide and Renal Outcomes in Type 2 Diabetes. *N Engl J Med*. 2017 Aug 31;377(9):839-848.
30. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB; DEVOTE Study Group. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *N Engl J Med*. 2017 Aug 24;377(8):723-732.
31. Gallo A, Giral P, Carrié A, Carreau V, Béliard S, Bittar R, Maranghi M, Arca M, Cluzel P, Redheuil A, Bruckert E, Rosenbaum D. Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia. *J Clin Lipidol*. 2017 May - Jun;11(3):704-711
32. Di Costanzo A, D'Erasmo L, Polimeni L, Baratta F, Coletta P, Di Martino M, Loffredo L, Perri L, Ceci F, Montali A, Girelli G, De Masi B, Angeloni A, Catalano C, Maranghi M, Del Ben M, Angelico F, Arca M. Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically-versus genetically-driven excess fat hepatic storage. *Atherosclerosis*. 2017 Feb;257:232-239.
33. Lamartina L, Montesano T, Trulli F, Attard M, Torlontano M, Bruno R, Meringolo D, Monzani F, Tumino S, Ronga G, Maranghi M, Biffoni M, Filetti S, Durante C. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. *Endocrine*. 2016 Nov;54(2):467-475.
34. Cohen O, Filetti S, Castañeda J, Maranghi M, Glandt M. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump. *Diabetes Care*. 2016 Aug;39 Suppl 2:S180-6.
35. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee.; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016 Jul 28;375(4):311-22
36. Lamartina L, Grani G, Biffoni M, Giacomelli L, Costante G, Lupo S, Maranghi M, Plasmati K, Sponziello M, Trulli F, Verrienti A, Filetti S, Durante C. Risk Stratification of Neck Lesions Detected Sonographically During the Follow-Up of Differentiated Thyroid Cancer. *J Clin Endocrinol Metab*. 2016 Aug;101(8):3036-44.
37. Minicocci I, Tikka A, Poggiogalle E, Metso J, Montali A, Ceci F, Labbadia G, Fontana M, Di Costanzo A, Maranghi M, Rosano A, Ehnholm C, Donini LM, Jauhiainen M, Arca M. Effects of angiotensin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism. *J Lipid Res*. 2016 Jun;57(6):1097-107.
38. Verrienti A, Carbone A, Bellitti P, Fabiano MC, De Rose RF, Maranghi M, Lucia P, Durante C, Rosignolo F, Pecce V, Sponziello M, Puppini C, Costante G, Bruno R. A novel double mutation val648ile and val804leu of ret proto-oncogene in multiple endocrine neoplasia type 2. *Endocr Pract*. 2015 Aug 6.
39. Montali A, Truglio G, Martino F, Ceci F, Ferraguti G, Ciociola E, Maranghi M, Gianfagna F, Iacoviello L, Strom R, Lucarelli M, Arca M. Correction: Atherogenic Dyslipidemia in Children: Evaluation of Clinical, Biochemical and Genetic Aspects. *PLoS One*. 2015 Jul 15;10(7).
40. Maranghi M, Carnovale A, Durante C, Tarquini G, Tiseo G, Filetti S. Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes. *Expert Opin Drug Metab Toxicol*. 2015 Jan;11(1):125-37. doi: 10.1517/17425255.2015.986457.
41. Barbarossa G, Renzi A, D'Erasmo L, Gallo A, Grieco E, Rossetti M, Carnovale A, Santilli M, Mandosi E, Coletta P, Pergolini D, Morano S, Maranghi M. The relation between glycemic control and HDL-C in type 2 diabetes: a preliminary step forward? *Diabetes Res Clin Pract*. 2014 Jan 8. pii: S0168-8227(14)00022-9. doi: 10.1016/j.diabres.2013.12.061.
42. Minicocci I, Santini S, Cantisani V, Stitzel N, Kathiresan S, Arroyo JA, Martí G, Pisciotta L, Noto D, Cefalù AB, Maranghi M, Labbadia G, Pigna G, Pannozzo F, Ceci F, Ciociola E, Bertolini S, Calandra S, Tarugi P, Averna M, Arca M. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. *J Lipid Res*. 2013 Dec;54(12):3481-90.
43. Arca M, Minicocci I, Maranghi M. The angiotensin-like protein 3: a hepatokine with expanding role in metabolism. *Curr Opin Lipidol*. 2013 Aug;24(4):313-20
44. Robciuc MR*, Maranghi M*, Lahikainen A, Rader D, Bensadoun A, Oorni K, Metso J, Minicocci I, Montali A, Ciociola E, Ceci F, Arca M, Ehnholm C, Jauhiainen M. Angptl3 deficiency is associated

- with increased insulin sensitivity, lipoprotein lipase activity and decreased serum free fatty acids . *Arterioscler Thromb Vasc Biol.* 2013 Jul;33(7):1706-13
45. Minicocci I, Cantisani V, Poggiogalle E, Favari E, Zimetti F, Montali A, Labbadia G, Pigna G, Pannozzo F, Zannella A, Ceci F, Ciociola E, Santini S, Maranghi M, Vestri AR, Ricci P, Bernin F, Arca M. Functional and morphological vascular changes in subjects with familial combined hypolipidemia: an exploratory analysis. *Int J Cardiol.* 2013 Oct 9;168(4):4375-8
 46. Kaye SM, Maranghi M, Bogl LH, Kaprio J, Hakkarainen A, Lundbom J, Lundbom N, Rissanen A, Taskinen MR, Pietiläinen KH. Acquired liver fat is a key determinant of serum lipid alterations in healthy monozygotic twins. *Obesity (Silver Spring).* 2012 Dec 12.
 47. Coletta P., Barbarossa G., Pergolini D., D'Erasmus L, Renzi A., Mercuri L., Anatra M. G., Ciociola E, Verrienti A, Maranghi M Genetic determinants and early carotid atherosclerosis: is there a role for the ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP-1) K121Q polymorphism? Preliminary results in non diabetic individuals. *Endocrine.* 2012 Dec;42(3):749-51.
 48. Maranghi M, Prudente S, D'Erasmus L, Morini E, Ciociola E, Coletta P, Verrienti A, Arciello S, Copetti M, Pellegrini F, Santini SA, Morano S, Filetti S, Trischitta V. The ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) K121Q polymorphism modulates the beneficial effect of weight loss on fasting glucose in non-diabetic individuals. *Nutr Metab Cardiovasc Dis.* 2012 Mar 6.
 49. Yetukuri L, Huopaniemi I, Koivuniemi A, Maranghi M, Hiukka A, Nygren H, Kaski S, Taskinen MR, Vattulainen I, Jauhiainen M, Orešič M. High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. *PLoS One.* 2011;6(8):e23589.
 50. Bogl LH, Maranghi M, Rissanen A, Kaprio J, Taskinen MR, Pietiläinen KH. Dietary omega-3 polyunsaturated fatty acid intake is related to a protective high-density lipoprotein subspecies profile independent of genetic effects: a monozygotic twin pair study. *Atherosclerosis.* 2011 Dec;219(2):880-6.
 51. Maranghi M, Hiukka A, Badeau R, Sundvall J, Jauhiainen M, Taskinen MR. Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: A FIELD substudy. *Atherosclerosis.* 2011 Nov;219(1):259-65.
 52. Mastroianno S, Tortolano M, Scillitani A, D'Aloiso L, Verrienti A, Bonfitto N, De Bonis A, D'Agruma L, Muscarella LA, Guarnieri V, Dicembrino F, Maranghi M, Durante C, Filetti S. Coexistence of multiple endocrine neoplasia type 1 and type 2 in a large Italian family. *Endocrine.* 2011 Dec;40(3):481-5.
 53. Durante C, Tallini G, Puxeddu E, Sponziello M, Moretti S, Ligorio C, Cavaliere A, Rhoden KJ, Verrienti A, Maranghi M, Giacomelli L, Russo D, Filetti S. BRAF V600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. *Eur J Endocrinol.* 2011 Sep;165(3):455-63.
 54. Irace C, Rossetti M, Carallo C, Morano S, Vespertini V, Mandosi E, Maranghi M, Fiorentino R, Filetti S, Gnasso A. Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. *Acta Diabetol.* 2011 Feb 9.
 55. Colotto M, Maranghi M, Durante C, Rossetti M, Renzi A, Anatra MG. PFAPA syndrome in a young adult with a history of tonsillectomy. *Intern Med.* 2011;50(3):223-5. Epub 2011 Feb 1.
 56. Sponziello ML, Bruno R, Durante C, D'Agostino M, Corradino R, Giannasio P, Ciociola E, Ferretti E, Maranghi M, Verrienti A, De Toma G, Filetti S, Russo D. Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. *Horm Metab Res.* 2011 Jan;43(1):22-5.
 57. Hiukka A, Maranghi M, Matikainen N, Taskinen MR. PPARalpha: an emerging therapeutic target in diabetic microvascular damage. *Nat Rev Endocrinol.* 2010 Aug;6(8):454-63. Epub 2010 Jun 22. Review. Erratum in: *Nat Rev Endocrinol.* 2010 Sep;6(9):476.
 58. Castellone MD, Verrienti A, Magendra Rao D, Sponziello M, Fabbro D, Muthu M, Durante C, Maranghi M, Damante G, Pizzolitto S, Costante G, Russo D, Santoro M, Filetti S. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with pheochromocytoma and medullary thyroid carcinoma: functional characterization. *Clin Endocrinol (Oxf).* 2010 Oct;73(4):529-34.
 59. Maranghi M, Pugliese F, Cianci R, Colotto M, Durante C, Anatra MG, Coletta P, Mercuri S, Rossetti M, Morano S, Filetti S. Atherosclerosis renal artery stenosis and in-stent restenosis in a diabetic

- patient: Targeting on diabetic dyslipidemia is a key intervention. *J Endocrinol Invest*. 2010 Apr;33(4):284-5.
60. Sponziello M, Scipioni A, Durante C, Verrienti A, Maranghi M, Giacomelli L, Ferretti E, Celano M, Filetti S, Russo D. Regulation of sodium/iodide symporter and lactoperoxidase expression in four human breast cancer cell lines. *J Endocrinol Invest*. 2010 Jan;33(1):2-6.
 61. Gatti A, Maranghi M, Bacci S, Carallo C, Gnasso A, Mandosi E, Fallarino M, Morano S, Trischitta V, Filetti S. Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes. *Diabetes Care*. 2009 Aug;32(8):1550-2.
 62. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. *J Clin Endocrinol Metab*. 2007, 92(2): 450-5.
 63. Ronga G, Bruno R, Puxeddu E, Calcinaro F, Montesano T, Travascio L, Colandrea M, Durante C, Maranghi M, Filetti S, Russo D. Radioiodine uptake in non-lactating mammary glands: evidence for a causative role of hyperprolactinemia. *Thyroid*. 2007, 17(4): 363-6.
 64. Montesano T, Durante C, Attard M, Crocetti U, Meringolo D, Bruno R, Tumino S, Al-Nahhas A, Rubello D, Colandrea M, Maranghi M, Travascio L, Ronga G, Torlontano M. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. *Biomedicine & Pharmacotherapy* 2007, 61(8): 468-71 .
 65. Maranghi M, Coletta P, Durante C, Pergolini D, Filetti S. Malattia cardiovascolare e sindrome metabolica: oggi e domani. *Recenti Progressi in Medicina*. 2006, 97 (12): 719-26.
 66. Romagnoli E, Carnevale V, Calandra P, D'Erasmo E, De Geronimo S, Pepe J, Manfredi G, Maranghi M, Aliberti G, Minisola S. Impact of fractures on health care in a major university hospital in Rome. *Aging Clin Exp Res*. 2003, 15(6): 505-11.
 67. Romagnoli E, Carnevale V, Nofroni I, D'Erasmo E, Paglia F, De Geronimo S, Pepe J, Raejntroph N, Maranghi M, Minisola S.: Quality of life in ambulatory postmenopausal women: the impact of reduced bone mineral density and subclinical vertebral fractures. *Osteoporos Int*. 2004, 15(12): 975-80.
 68. Filetti S, Durante C, Maranghi M. A genetic based disease management in inherited cancer syndromes: the multiple endocrine neoplasia model. *Supportive & Palliative Cancer Care*. 2006, 2 (suppl. 2): 13-16.
 69. Durante C, Romagnoli E, Maranghi M, D'Aloiso L, Minisola S, D'Erasmo E, Filetti S. Hyperparathyroidism in multiple endocrine neoplasia type IIA. *Clinical Cases in Mineral and Bone Metabolism*. 2006, 3 (2): 162-6
 70. Violi F, Loffredo L, Maranghi M. Effect of vitamins E and C on transplant-associated atherosclerosis. *Lancet*. 2002, 360 (9331): 486.
 71. Iuliano L, Micheletta F, Maranghi M, Frati G, Diczfalusy U, Violi F Bioavailability of vitamin E as function of food intake in healthy subjects: effects on plasma peroxide-scavenging activity and cholesterol-oxidation products. *Arterioscler Thromb Vasc Biol*. 2001, 21 (10): E34-7.

1.

I declare under full personal responsibility that the information contained in the present CV are true and accurate.

Rome, 26/Feb/2026

